XML 44 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]  
Summary of Components of Rent Expense

The table below summarizes the components of rent expense for the fiscal year ended December 31, as follows:

 

     2013     2012     2011  

Rent expense

   $ 2,612,899      $ 2,932,104      $ 4,193,433   

Sublease income

     (53,726     (411,885     (424,847
  

 

 

   

 

 

   

 

 

 

Rent expense, net

   $ 2,559,173      $ 2,520,219      $ 3,768,586   
  

 

 

   

 

 

   

 

 

 
Future Minimum Payments Under All Leases and Bond Payable

Future minimum payments under all leases, bond payable and loan payable at December 31, 2013 are as follows:

 

     Bonds
Payable
     Loan(1)
Payable
     Capital
Leases
     Operating
Leases
 

2014

   $ 136,852       $ 4,322,035       $ 24,284       $ 1,917,423   

2015

     —          4,322,035         21,591         1,912,217   

2016

     —          1,440,678         9,454         1,968,459   

2017

     —          —          —          2,014,706   

2018

     —          —          —          2,061,260   

Thereafter

     —          —          —          8,196,910   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total minimum lease payments

     136,852         10,084,748         55,329       $ 18,070,975   
           

 

 

 

Less amounts representing interest

     11,852         704,963         4,591      
  

 

 

    

 

 

    

 

 

    

Principal amounts of bond payable, loan payable and capital lease obligations

     125,000         9,379,785         50,738      

Less current maturities

     125,000         3,857,971         20,936      
  

 

 

    

 

 

    

 

 

    

Bond payable, loan payable and capital lease obligations, less current maturities

   $ —         $ 5,521,814       $ 29,802      
  

 

 

    

 

 

    

 

 

    

 

(1) Approximately $3.8 million received as initial disbursement of the loan provided under the CIRM Loan Agreement is not included. In April 2013, we entered into an agreement with CIRM under which CIRM will provide up to approximately $19.3 million to help fund preclinical development and IND-enabling activities of our HuCNS-SC cells for Alzheimer’s disease. The funding is in the form of a forgivable loan, in accordance with mutually agreed upon terms and conditions and CIRM regulations, and is expected to be disbursed periodically by CIRM over the four-year project period subject to a number of preconditions, including the achievement of certain progress milestones and compliance with certain financial covenants. The loan is unsecured and the term of the loan is ten years and may be extended under certain circumstances.